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ABSTRACT: Both SULF1 and SULF2 enzymes are undetectable in normal adult liver tissue despite their high 
level expression during fetal development.  Most hepatocellular carcinomas unlike the normal adult liver, 
however, express variable levels of these enzmyes with a small proportion not expressing either SULF1 or 
SULF2.  SULF1 expression, however, is not restricted to only fetal and tumour tissues but is also abundant 
in liver tissues undergoing injury-induced tissue regeneration as we observed during fatty liver degeneration, 
chronic hepatitis and cirrhosis. Unlike SULF1, the level of SULF2 activation during injury induced regeneration, 
however, is much lower when compared with fetal or tumour growth. Although a small fraction of liver tumours 
and some liver tumour cell lines can grow in the absence of Sulf1 and/or Sulf2, the in vitro overexpression of 
these genes further confirms their growth promoting effect while transient reduction in their levels by 
neutralisation antibodies reduces growth.  Hedgehog signalling appeared to regulate the growth of both 
Hep3B and PRF5 cell lines since cyclopamine demonstrated a marked inhibitory effect while Sonic hedgehog 
(SHH) over- expression promoted growth.  All Sulf isoforms promoted SHH-induced growth although the level 
of increase in PRF5 cell line was higher with both Sulf2 variants than Sulf1.  In addition to promoting growth, 
the Sulf variants, particularly the shorter Sulf2 variant markedly promoted PRF5 cell migration in a scratch 
assay. The SULF1/SULF2 activation thus does not only promote regulated fetal growth and injury induced 
liver regeneration but also dysregulated tumour growth. 
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INTRODUCTION:  
Liver tumours like most other cancers promote tumour growth by activating a number of cell signalling pathways 
(Giakoustidis A et al. 2015).  Most growth promoting cell signalling pathways do not only require ligand receptor 
interaction but also heparan sulfate proteoglycan (HSPG) co-receptor participation to facilitate ligand/receptor 
interaction (Merry and Gallagher 2002). HSPGs constitute both cell surface and ECM located molecules. The 
precise role of HSPGs, however, is determined by their sulfation status initially specified intracellularly by 
sulfotransferases (Merry and Gallagher 2002; Ashikari-Hada S et al. 2004; Ford- Perriss M1 et al. 2002) that 
can be further edited extracellularly by two endosulfatases called Sulf1 and Sulf2 (Dhoot et al. 2001; Morimoto-
Tomita et al. 2002; Rosen and Lemjabbar-Alaoui 2010). These enzymes hydrolyse 6-O sulfates of HSPGs that 
have differential effects on the activities of different cell signalling pathways since 6-O sulfation is required by 
certain signalling pathways such as receptor tyrosine kinase facilitated cell signalling (Lai et al. 2003; Uchimura 
et al. 2006; Wang et al. 2004). The activities of such signalling pathways are thus inhibited by these enzymes 
by the removal of 6-O sulfates (Dhoot 2012). The activities of some other cell signalling pathways such as Wnt 
or GDNF in contrast are promoted by these enzymes as HSPG de-sulfation facilitates their cell surface 
ligand/receptor interaction by ligand release from HSPG binding in ECM (Dhoot et al. 2001; Sahota and Dhoot 
2009; Morimoto-Tomita et al. 2002; Ai et al. 2003; Dhoot 2012; Ai et al. 2007). Changes in Sulf1/Sulf2 
expression in normal and pathological tissues could thus indicate their cell signalling activity in such tissues. 
The role of Sulf1/Sulf2 in HCC growth, however, is not clear due to some conflicting reports of Sulf1/Sulf2 
upregulation (Bret et al. 2011; Gill et al. 2011; Gill et al. 2012; Gill et al. 2014; Nawroth et al. 2007; Lemjabbar-
Alaoui et al. ; Rosen and Lemjabbar-Alaoui 2010) as well as the downregulation of such enzymes in HCC (Lai 
et al. 2008a; Lai et al. 2006; Xu G et al. 2014). This therefore raises the question as to whether Sulf1 or Sulf2 
enzymes are preferentially expressed in normal adult or fetal liver or tumour tissues. This study was undertaken 
to determine if it is the normal or the tumour tissues that express high levels of Sulf1 or Sulf2 since a number 
of studies have reported the upregulation of Sulf1 and Sulf2 enzymes in tumours (Kroy DC et al. 2010; Gill et 
al. 2012; Gill et al. 2014; Bret et al. 2011; Nawroth et al. 2007) while others have reported the down-regulation 
of these enzymes in tumour tissues (Lai et al. 2006; Lai et al. 2008b; Xu G et al. 2014) compared with normal 
tissues thus implying that Sulfs and particularly Sulf1 is a tumour suppressor rather than a tumour growth 
enhancer.  Since HCC develops over a long time period and is often preceded by additional steps such as 
hepatitis and cirrhosis, this analysis also included some other liver samples likely to activate cell signalling in 
response to liver damage-induced regeneration.  It is critical to determine whether Sulf1 or Sulf2 are positively 
or negatively regulated in normal and regenerating or tumour tissues. 
Hepatocellular carcinoma (HCC) is usually preceded by chronic hepatitis virus infection that includes both 
hepatitis virus B and C (Kwon YC et al. 2015; Tarocchi M et al. 2014). Such viral infection can change 
transcriptional activity to modify growth regulation by impacting cell signalling.  In addition to HCC, other 
conditions such as fatty liver disease that leads to lipid accumulation in hepatocytes result in hepatocyte 
apoptosis/cell necrosis due to liver cell injury. This triggers inflammatory response implicating many 
cytokines/chemokines whose activities may be enhanced by Sulf1 and/or Sulf2 activation as for example has 
been shown for SDF1 (Uchimura et al. 2006). This could induce a transient change in gene expression or may 
even lead to HCC progression at later stages but such non-tumour tissues  are not really normal controls for 
the purpose of Sulf expression in normal versus HCC.  A de-regulated cytokine balance has been proposed to 
trigger the sequence from steatosis to non- alcoholic steatohepatitis, ultimately leading to liver cirrhosis and 
cancer (Kroy DC et al. 2010). This thus requires careful distinction of normal from HCC with several intermediate 
stages that can also activate Sulf1/Sulf2 enzymes in such cells but can neither be classified as tumour or 
normal liver. 
Our earlier RT PCR analysis of human fetal and adult normal canine liver and some immunocytochemical 
analysis of some tumours demonstrated the increased expression of Sulf1/Sulf2 in a number of canine and 
some human tumours since normal adult liver unlike the fetal liver did not express detectable levels of Sulf1 or 
Sulf2 (Gill et al. 2012).  In the present study, we undertook further analysis of both Sulf1 and Sulf2 in a larger 
number of normal adult (n=28), fetal (n=12) and HCC (n=105) human liver samples and 4 liver cell lines. We 
also carried out Sulf1/Sulf2 analysis of not only HCC and several normal livers but also a number of other liver 
samples with a potential to activate Sulf1/Sulf2 expression due to inflammatory response or a change in 
metabolism or activation of developmental programme due to regenerative response initiated by hepatocytic 
injury. 
This study confirmed the up-regulation of Sulf1 and Sulf2 enzymes in a large proportion of the hepatocellular 
carcinomas.  The Sulf1/Sulf2 up-regulation, however, was not restricted to only tumour growth but also 
activated during liver damage induced-liver repair/regeneration during HCC-preceding stages.  This study thus 
supports a hypothesis that Sulf1/Sulf2 activation relates to not only increased cell- signalling during normal 
development and regeneration (Gill et al. 2010; Hitchins et al. 2013) but also during abnormal in vivo and in 
vitro growth.  This is further confirmed by Sulf1 and Sulf2 induced in vitro growth promotion of liver tumour cell 
lines. 
Materials and methods: 
Immunocytochemical procedures: Paraffin human fetal tissue sections were obtained from the US Biomax 
and MRC/Wellcome Human Developmental Biology Resource at ICH, UCL following ethical regulation 
approval.  Other human tissues were obtained from US Biomax. The paraffin sections of all tissues were stained 
using immunofluorescence procedure as described previously (Gill et al. 2010). The binding of rabbit Sulf1 
antibodies A and C diluted 1/200 and rabbit Sulf2 antibodies N (1/300) and D (1/100) were visualised using 
goat anti-rabbit biotinylated IgG followed by streptavidin-conjugated Alexa Fluor 594 or Alexa Fluor 488 
fluorochrome.  The α- feto protein expression was analysed using mouse monoclonal antibody 3H8 supplied 
by Cell signalling at 1/100 dilution following citrate buffer pH 6.00 pre- treatment and detection by goat anti 
mouse immunoglobulin linked Alexa Fluor 488. Sections treated with pre-immune rabbit sera were similarly 
incubated with fluorochrome-labelled secondary antibodies as controls (not shown).  All fluorochrome-labelled 
secondary antibodies were diluted 1/400.  All primary antibody reactions were incubated overnight at 4°C 
followed by secondary antibody incubations for 1 hour each at room temperature. Labelled tissue sections 
were mounted in fluorescent mounting medium (Sigma Aldrich) containing 2.5 μg/ml DAPI for nuclear 
visualisation and photographed using a Leica DM4000B fluorescent microscope. 
For immunocytochemical quantification, the images were analysed using Volocity (version 6.3.1, PerkinElmer) 
software.  For each fluorophore, all pixels with an intensity greater than a given intensity threshold were defined 
as positively labelled.  From the resulting binarised image, any contiguous groups of pixels smaller than a given 
size threshold were excluded as noise.  The total area of the remaining pixels was then determined per image.  
Both thresholds were defined empirically based on representative images and then held constant for each 
fluorophore. The intensity thresholds used, on 8 bit images, were 91 (for the red and blue fluorophores) and 
103 (for the green fluorophore).  The size thresholds were 5 pixels (for the red fluorophore) and 10 pixels (for 
the green and blue fluorophores). 
The number of samples examined for immunohistochemical analysis of each group included two cores of each 
sample, the normal adult human (n=28), normal fetal (n=12), HCC (105), fatty liver degeneration (n=15), chronic 
hepatitis (n=22) and cirrhosis (n=29). Two regions of each sample were photographed for each tissue for 
immunohistochemical analysis. 
RT-PCR analysis: Total RNA from Hep3B, HepG2, SkHep1 and PRF5 cells (supplied by ATCC) was prepared 
using Trizol to generate cDNA with reverse transcriptase using random primers. The PCR of such samples 
was carried out using Sulf1 primers P23 (5’-CGAGGTTCAGAGGACGGATA-3’) and P24 (5’- 
GCCTCTCCACAGAATCATCC-3’) and Sulf2 primers 186 (5’- CAACTGTGTTCTCCCTGCTGGGT-3’) and 187 
(5’- CTGGAGCATGTTGGTGAATTCC-3’) to exons 5 and 9 generating 804bp Sulf1 and 802 bp Sulf2 PCR 
products.  Sense and antisense primers 5′- CTATGAGCTGCCTGACGGTC-3′ and 5′-
AGTTTCATGGATGCCACAGG-3′ were used to amplify 114 bp β-actin (nucleotides 798–912 bp). All PCR 
products following 40 amplification cycles were analysed in 2% agarose gels (Gill et al. 2014). 
Cell culture and transfection: Human Sulf1 and Sulf2 cDNA constructs (full length and a variant with deletion 
of exons 6, 7 and 18) were cloned into pcDNA3.  Human liver cell lines Hep3B and PRF5 were grown in 
Dulbecco׳s modified Eagle׳s (DMEM) medium with 10% foetal calf serum as described previously (Gill et al. 
2014). Over- expression of Sulf1 or Sulf2 variants in both these cell lines was achieved by transfection with 
Biorad transfectin lipid reagent. The transfection of Sulf1 and Sulf2 variants also included the transfection with 
an EGFP expression vector while the control cells were transfected with EGFP/pcDNA3 alone. To enrich the 
mixed population of transfected cells, the normal growth medium was changed to DMEM/10%FCS with 800 
µg/ml G418 following 48 h of growth in the normal medium. The Sulf1/Sulf2 over-expression by transfection 
was confirmed by the RT PCR analysis. Such transfected cells were used for in vitro and in vivo assays 
following 2–6 weeks of growth in G418 containing medium.  For in vitro proliferation assays, 10,000 cells/well 
were seeded in multiple 24-well plates and the trypsinised cells counted after 1, 2, 3, 4 and 5 days of culture 
or only once after 5 days culture in certain assays (Gill et al. 2014). In addition to each sample consisting of a 
minimum of three replicates for each stage, each experiment was repeated three times. 
For scratch assays, cells were grown until confluent before scratching with a pipette tip to obtain two 
perpendicular clear lines.  Such scratches or clear lines were photographed at 0, 24, 48, 72 and 96 hours using 
an inverted Leica microscope. Distances between the edges of cleared lines were calculated by measuring the 
change in clear area at different time points following the change from time 0 by subtraction.  A total of 10 such 
scratches were measured per group for each experiment repeated three times. 
Statistical analysis: Statistical analysis was preformed using either a one-way ANOVA or a two-way ANOVA, 
where data depicting a P-value < 0.05 was considered statistically significant. To enable multiple comparisons, 
a Tukey’s test was used to determine significant variation between Sulf transfects to their eGFP controls or 
between full length Sulf isoforms and their shorter variants. 
 
RESULTS: 
SULF1/SULF2 expression in normal adult, fetal and HCC tissues: This immunocytochemical analysis 
confirmed our earlier RT PCR study of little or no SULF1/SULF2 expression in normal adult liver using a number 
of different samples (n=28) but expression of both these enzymes in a number of fetal liver samples (n=12) 
(Figure 1). The immunohistochemical analysis of 105 human liver HCC samples showed the expression of 
either both SULF1 and SULF2 or only one of these enzymes in over 80% (+ 5%) of the HCC samples.  A 
proportion (15-25%) of the HCC samples, however, did not express either of these two enzymes (Figure 2). 
The composition of both SULF1 and SULF2 variants also varied in HCC samples with some samples 
expressing mainly full length catalytically active SULF1 or SULF2 while others expressing only the shorter 
variants without the catalytically active exon 6 (Figure 2) (Gill et al. 2012). The normal 4-5 month fetal livers in 
contrast only expressed the full length (Figure 1) and no shorter variants (not shown). These variants vary in 
their cell signalling activities as described in our earlier study (Gill et al. 2012; Gill et al. 2014). The relative 
proportions of full length (SULF1A & SULF2A) and shorter variants (SULF1B & SULF2B) of both SULF1 and 
SULF2 also varied amongst these samples (Figure 2). Unlike SULF1, SULF2 demonstrated a greater 
abundance of full length enzyme compared with the shorter variant (Figure 2G).  RT PCR analysis of 4 different 
human liver cell lines demonstrated little or no expression of Sulf1 or Sulf2 (Figure 2H).  A trace amount of 
Sulf1 was detected in only SkHep1 cells with no detectable expression in PRF5, Hep3B or HepG2 cells under 
normal culture conditions.  Similarly, only a trace amount of Sulf2 was detectable in HepG2 with no expression 
being apparent in PRF5, Hep3B or SkHep1 cells. 
SULF1/SULF2 expression is also activated in response to fatty liver degeneration, chronic hepatitis 
and cirrhosis. To determine if SULF1/SULF2 expression in liver tissue was related to only fetal development 
and the onset of tumorigenesis or also related to tissue repair/regeneration in response to liver damage, we 
examined the expression of both these enzymes in a number of different human liver samples including not 
only normal and HCC samples but also samples with fatty liver degeneration (n=15), chronic hepatitis (n=22) 
and cirrhosis (n=29) (Figures 3 & 4). High levels of SULF1 expression are apparent in all individuals with fatty 
liver degeneration showing not only very large but also a number of quite small hepatocytes expressing varied 
levels of SULF1 (Figure 3.C1- C2).  Different liver samples with chronic hepatitis (Figure 3.D1-D2) also 
expressed high levels of SULF1 in all samples although the distribution of SULF1 varied in different samples.  
For example, SULF1 expression level in some samples is much higher around the nucleus as well as extending 
into some nuclei as is indicated by some white arrows (Figure 3.D2). Similarly, high SULF1 expression is 
apparent in all cirrhotic livers (Figure 3.E1-E2).  Although SULF1 expression is high in all such liver samples, 
their precise level of expression varied in different regions.  SULF2 expression was also observed in some liver 
samples with fatty liver degeneration, chronic hepatitis and cirrhosis although its expression was apparent in 
only a small fraction of the samples and the SULF2 levels were much lower when compared with SULF1 levels 
(Figure 4). While SULF1 activation was detected in all such samples, a large proportion of liver samples with 
fatty liver degeneration, chronic hepatitis and cirrhosis thus did not show any SULF2 expression using 
immunocytochemical staining procedure in this study (Figure 4). 
SULF1/SULF2 expression in some adult livers could be related to tumour cell growth or hepatic 
damage-induced regeneration as indicated by the activation of α-fetoprotein. Liver retains the potential 
to repair itself in response to injury. We therefore analysed the expression of α-fetoprotein associated with cell 
proliferation although the precise mechanism of its function is not known (Wang S1 et al. 2012). We examined 
if SULF1/SULF2 expression is related to liver regeneration in samples with fatty liver degeneration, chronic 
hepatitis and cirrhosis using normal adult and HCC tumour tissues as negative and positive controls (Figure 
5). Immunocytochemical analysis showed no α-fetoprotein expression in normal adult liver but variable level of 
expression in different HCC tumours. This is indicated by only background staining of normal but much darker 
staining of not only HCC, but also liver samples representing fatty degeneration, chronic hepatitis and cirrhosis. 
All tissue samples with HCC, fatty liver degeneration, chronic hepatitis and cirrhosis showed variable levels of 
α-fetoprotein expression showing regional variation (Figure 5). 
Sulf1/Sulf2 expression levels modulate the growth of some liver tumour cells. The Sulf1/Sulf2 expression 
in a large majority of the liver tumours indicates their possible stimulatory role in promoting tumour growth even 
though a small proportion of primary tumours and a number of cell lines did not express any Sulf1 or Sulf2 and 
thus can grow in the absence of Sulf1/Sulf2.  We transfected the Hep3B and PRF5 cells with some shorter and 
full length variants of both Sulf1 and Sulf2 to determine if Sulf over-expression promoted or inhibited growth 
using EGFP transfection as a control. Once the transfected cell population had been selected by growth in 
G418 containing cell culture medium, the growth of such cells was compared with EGFP controls over 5 day 
time period.  Compared with PRF5, relative growth rate of Hep3B cells was slower (Figure 6). Nevertheless, 
both full length and shorter variant of Sulf1lacking exons 6 and 7 (HS1-67) increased growth of Hep3B cells 
although level of increase was higher with HS1-67 than HS1.  Both shorter and full length Sulf2 also promoted 
the growth of Hep3B cells with HS2 showing higher increase than HS2-67 (lacking exons 6 & 7) although the 
relative increase with Sulf2 over- expression was lower than Sulf1 over-expression (Figure 6). As was the case 
with Hep3B, transfection of PRF5 cells with both full length (HS1) and shorter variant (HS1-67) of Sulf1 also 
demonstrated increased growth. Over-expression of both shorter and full length Sulf2 also promoted growth of 
PRF5 cells (Figure 6). While the level of increased growth was slightly higher with Sulf1 than Sulf2 in Hep3b 
cells this was reversed in the PRF5 cells showing higher increase with Sulf2 than Sulf1 (Figure 6).  To further 
examine the role of Sulf1/Sulf2 in such tumour cell growth, we also added some SULF1 and SULF2 
neutralisation antibodies to decrease the levels of these enzymes in transfected cell cultures.  The addition of 
antibody C that reacts with all Sulf1 variants and antibody D that reacts with all SULF2 variants at the onset of 
the experiment demonstrated decreased levels of growth in both Sulf1 and Sulf2 transfected cells only during 
the first 3-4 days as no further antibody was added at a later stage (Figure 6). 
Hedgehog signalling regulates hepatocyte tumour growth that is further modulated by Sulfs:  To 
examine if Hedgehog signalling plays a role in the growth of Hep3B and PRF5 cells, we initially examined the 
effect of 5µM, 10µM and 20µM cyclopamine on their growth to rule out any off target effects described for 
certain cell lines (Meyers-Needham M1 et al. 2012).  All three cyclopamine concentrations showed a linear 
dose response although the effect was much lower at 5µM concentration and increased effect was observed 
at 20 µM concentration that we used in all subsequent experiments in this study. The addition of cyclopamine 
to both Hep3B and PRF5 cells for 5 days markedly inhibited the growth of these cells highlighting the role of 
Hedgehog signalling in their growth (Figure 7). The addition of SHH at 10ng/ml in contrast promoted growth in 
all PRF5 and Hep3B control and Sulf1/Sulf2 transfected cells (Figure 7).  The level of SHH-induced growth in 
PRF5 cells was greatest in both Sulf2 variant transfected cells when compared with the increase in Sulf1 
transfected cells (Figure 7). 
Some Sulf1/Sulf2 splice variants markedly enhance PRF5 cell motility: Further to the effect of Sulf1/Sulf2 
over-expression on growth, we also examined if the Sulf1/Sulf2 overexpression affected the cell migration. The 
transfection of PRF5 cells with full length Sulf1 showed little effect on cell migration during 48 hours although 
a small increase in migration was apparent during later stages of 72 and 96 hours. Compared with the full 
length Sulf1 (HS1), the migration of HS1-67 transfected cells showed considerably greater level of migration. 
The highest increase in cell motility, however, was observed with PRF5 transfection with shorter variant of Sulf2 
i.e. HS2-67 with the increase becoming apparent even after one day but with marked effects during subsequent 
stages of 2-4 days. 
 
DISCUSSION: 
The onset and progression of tumour growth is affected by a multitude of factors unique to each individual’s 
genomic composition and environmental exposure.  The key question, however, remains what drives such 
growth and how effectively the growth can be targeted using appropriate inhibitors. The activities of tumour 
growth drivers may be only marginally or highly dysregulated during early or late stages of tumour growth that 
often reflects the re-activation of a number of signalling pathways characteristic  of fetal and neonatal growth.  
Sulf1 and Sulf2 enzymes regulate the activities of a large number of signalling molecules in a negative or 
positive manner and therefore changes in their activities during development and tumour growth would indicate 
whether these enzymes act as tumour suppressors or tumour enhancers.  The present study demonstrated 
the down-regulation of both Sulf1 and Sulf2 in normal adult liver following high levels of their expression during 
fetal development promoting growth-related active cell signalling. This is compatible with increased expression 
of Sulfs during fetal development of many tissues (Gill et al. 2010; Hitchins et al. 2013) and during the 
development of different tumour types (Gill et al. 2012; Gill et al. 2014; Lemjabbar-Alaoui et al.). It, however, 
differs from some other studies reporting Sulf1 to be a tumour suppressor in liver (Lai et al. 2006; Lai et al. 
2008a; Xu G et al. 2014) thus implying higher level of expression in normal adult liver although some other 
adult tissues such as neuronal and skeletal tissues have been reported to continue expressing Sulf1/Sulf2 
throughout life (Joy et al. 2015; Zaman et al. 2016). Sulf1 activation, however is not unique to fetal or tumour 
growth since a number of other conditions including injury-induced repair can also activate these enzymes. 
Such activation thus could be related to an inflammatory response but also to hepatocyte degeneration that 
could promote both inflammation and regenerative response since the liver has a remarkable ability to heal 
itself upon injury. Regenerative response has a lot of similarities to fetal growth but is often additionally 
associated with injury-related inflammation.  The inflammatory cells themselves produce a number of cytokines 
and chemokines whose activities are regulated by the sulfation status of the HSPGs as for example Sulf1/Sulf2 
have been shown to promote SDF1 activity (Uchimura et al. 2006). The degenerative process has also been 
shown to activate some cell signalling pathways as for example Wnt signalling has been shown to promote 
age-related macular degeneration (Tuo J 2015). While Sulf1 plays an active role not only in fetal and tumour 
growth but also in liver damage induced regeneration, Sulf2 activity in the latter was considerably lower 
compared with Sulf1. 
The reason for variation in Sulf1/Sulf2 expression in different studies of HCC is not clear but could relate to 
many other conditions inducing Sulf1/Sulf2 changes in non- tumour liver that is not strictly normal as the liver 
has a great injury-induced regenerative potential. The Sulf1/Sulf2 expression in “normal” non-tumour liver is 
thus more complex due to its frequent fat accumulating hepatocytic degeneration leading to liver damage-
induced repair/regeneration. The present study demonstrates high SULF1 expression during fatty liver 
degeneration that may constitute only a small or large part of an apparently “normal” liver.  Any liver damage 
would promote its repair/regeneration by activating growth promoting signalling pathways similar to fetal liver 
development that clearly deploys Sulf1/Sulf2 activity.  Such liver regeneration is not restricted to only fatty liver 
degeneration but is also a response to any other damage leading to cirrhosis.  Cirrhosis is a complication of 
liver disease involving loss of liver cells and irreversible scarring of the liver often associated with alcohol 
consumption and persistent viral hepatitis B and C infections.  Cell signalling plays a critical role in development 
and regeneration of many tissues but the regeneration is often intimately associated with inflammation in 
response to tissue damage. The inflammatory cells themselves produce a number of cytokines and chemokines 
whose activities are further regulated by the sulfation status of the HSPGs. 
Sulfs have been described to play a major role in normal growth as well as tumour growth but less is known 
about their role in virus uptake by the cell during many viral infections.  Heparan sulfate (HS) acts as a co-
receptor for the cellular entry of viruses including not only hepatitis B and C viruses (Barth H et al. 2003; Schulze 
A et al. 2007) but also many other viruses such as herpes simplex virus 1 (Shukla D et al.). Viral uptake thus 
is particularly relevant to liver that is prone to many viral infections including hepatitis that often precedes the 
development of hepatocellular carcinoma. Virus entry into hepatocytes is a multi-step process in which many 
factors are involved including HSPGs whose sulfation levels play a critical role in this process (Tátrai P1 et al. 
2010; Xu Y et al. 2015). Interactions between HSPGs and its ligands are fine-tuned by the sulfation pattern of 
its heparan sulfate (Ashikari- Hada S et al. 2004). Hepatitis-related inflammation and HSPG-sulfation regulated 
virus uptake by hepatocytes can thus further modulate Sulf1/Sulf2 expression in such cells since many of these 
processes are likely to activate cell signalling pathways requiring Sulf1/Sulf2 modulation. Immunochemical 
staining with SULF1 and SULF2 antibodies in the present study detected raised levels of particularly SULF1 
but only occasionally of SULF2 in many such samples that were not tumorigenic.  Although Sulf1/Sulf2 up-
regulation could relate to a number of different conditions, some of these changes appeared to be related to 
regenerative growth process as indicated by the activation of α-fetoprotein in such samples that was not 
detectable in the normal adult liver. We did not, however, quantify the precise correlation of Sulf1/Sulf2 
activation with α-fetoprotein expression in this study. 
The expression of Sulf1/Sulf2, however, is not essential for growth as is indicated by the observations that a 
number of liver cell lines in vitro and a small proportion of the primary tumours in vivo did not express any 
SULFs.  We therefore further analysed the role of Sulf1/Sulf2 in tumour growth by over-expressing these 
enzymes by transfection of Hep3B and PRF5 liver cell lines.  Both these cell lines grew well in culture but the 
over-expression of individual full length as well as shorter variants of both Sulf1 and Sulf2 promoted their growth 
further with some quantitative differences in their rate of growth. Both Sulf1 and Sulf2 thus have the potential 
to modify hepatocyte cell growth if and when required in vivo conditions. The positive stimulatory growth of 
both liver cell lines by Sulf1 as well as Sulf2 was further confirmed by their reduced growth upon treatment with 
neutralisation antibodies. 
The similarity of growth promotion by both full length and shorter SULF1 and SULF2 variants in these cultures 
may relate to the presence of a number of growth factors in FCS containing medium.  It could be more 
informative to analyse possible functional differences using more defined media in futher studies. This study 
also showed the shorter Sulf1 and Sulf2 variants particularly HS2-67 to markedly promote cell motility. It is 
therefore possible that HS2-67 expression could promote tumour metastasis by enhancing specific cell 
signalling pathways. 
Any number of cell signalling pathways can promote tumour growth. The Hedgehog signalling appeared to play 
a major role in the growth of both Hep3B and PRF5 cells since their growth was markedly inhibited by 
cyclopamine but promoted by SHH protein exposure.  It was not, however, clear which variants preferentially 
promoted SHH signalling since all isoforms appeared to promote growth except with a much higher rate of 
growth in the presence of both Sulf2 variants in comparison with Sulf1. 
This study thus did not show any evidence of Sulf1 being a tumour suppressor although Sulf1 and Sulf2  can 
demonstrate differential activation during tumour growth and particularly during liver damage-induced tissue 
regeneration. 
  
FIGURE LEGENDS: 
Figure 1: Immunocytochemical staining of normal adult and 4 & 5 month fetal liver stained for total Sulf1 and 
Sulf2 expression using immunofluorescence procedure. Scale bar = 100µM. 
 
  
  
Figure 2: Immunocytochemical staining of liver samples from normal and two different HCC patients each 
stained for catalytically active Sulf1( A, B, C) & Sulf2 (, D, E, F) labelled green, and for total Sulf1 (A1, B1, C1) 
and Sulf2 (D1, E1, F1) labelled red using immunofluorescence procedure. G demonstrates the quantitative 
differences (relative proportions:%age) in the expression patterns of both Sulf1 and Sulf2 in normal versus 
HCC tumours, **p<0.001, ***p<0.0001.  G shows the Sulf1 and Sulf2 mRNA expression in 4 liver cell lines and 
a positive control using RT PCR analysis. Scale bar = 100µM. 
 
Figure 3: Sulf1 expression pattern examined by immunofluorescence using antibody C that detects total Sulf1 
in 2 liver samples from different individuals to highlight any individual differences in each case of fatty liver 
degeneration (C1-C2), chronic hepatitis (D1-D2) and cirrhosis  (E1-E2) alongside HCC (B1-B2) and normal 
(A1-A2) livers as positive and negative controls. D2 also includes a magnified region of thissection to highlight 
the presence of SULF1 in some nuclei but not others as indicated by the arrows. F summarises the quantitative 
differences in Sulf1 expression in normal versus different pathological conditions, ***p<0.0001. The quantitative 
differences for each group represent a number of samples while some of the images shown in this figure 
represent minimal as well as maximal staining. Scale bar = 100µM. 
 
Figure 4: Sulf2 expression pattern by immunofluorescence using antibody that detects total Sulf2 in 2 liver 
samples from different individuals to highlight any individual differences in each case of fatty liver degeneration 
(C1-C2), chronic hepatitis (D1-D2) and cirrhosis  (E1-E2) alongside HCC (B1-B2) and normal (A1-A2) livers as 
positive and negative controls. F summarises the quantitative differences in Sulf2 expression in normal versus 
different pathological conditions, *p<0.05, ***p<0.0001. Scale bar = 100µM. 
 
Figure 5: The immunocytochemical expression pattern of α-feto protein using immunofluorescence procedure 
in 2 liver samples from different individuals in each case of fatty liver degeneration (C1-C2), chronic hepatitis 
(D1-D4) and cirrhosis  (E1- E4) alongside HCC (B1-B4) and normal (A1-A4) livers as positive and negative 
controls. Scale bar = 100µM. 
 
 
 
 
Figure 6: The effect of over-expression of full length (HS1 and HS2) and Shorter Sulf1 (HS1-67) and Sulf2 
(HS2-67) variants on the growth of Hep3B (A, B) and PRF5 (C, D) cells over 5 days of culture.  Compared with 
the control (EGFP), over-expression of all Sulf1 and Sulf2 variants showed increased growth. The growth rate 
of PRF5 cells with both full length and shorter Sulf1 (HS1, HS1-67: E & G) and Sulf2 (HS2, HS2-67: F, H) 
expression was significantly reduced by 200ng/ml Sulf1 and 200ng/ml Sulf2 neutralisation antibodies C and D 
at days 3 and 4 respectively, *p<0.05, **p<0.001,***p<0.0001. 
 
Figure 7: The effect of 10ng/ml SHH and 20µM cyclopamine on the growth of Hep3B (A) and PRF5 (B) cells 
transfected with different Sulf1 and Sulf2 variants over 5 days in culture.  C: the migration of PRF5 cells 
transfected with different Sulf1 and Sulf2 variants over 4 day time period, *p<0.05, **p<0.001,***p<0.0001. 
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